Nine Months on a Pig Kidney: Landmark 'Bridge' Transplant Renews China's Xenotransplantation Debate

A gene-edited pig kidney has done something no pig organ had done before: it kept a 66-year-old man alive for more than nine months — working inside him, dialysis-free, until a human kidney became available. The case, detailed this month in The Lancet by a team at Massachusetts General Hospital, is being reported in China as the first time a pig kidney served as a deliberate "bridge" to a human transplant, and it has turned a fringe-sounding procedure into a serious topic of conversation on Chinese social media.

The patient, identified in Chinese write-ups by his first name, Andrews, had been on the transplant waiting list with kidney failure and diminishing odds — matching depends on a suitable donor dying in time, and his health might not hold. When he learned a Massachusetts hospital was experimenting with pig kidneys, he volunteered. "I'm going to die anyway," he reasoned, according to one widely shared Chinese post. "I might as well contribute something to humanity." The genetically edited organ was implanted in early 2025. For nine months it produced urine and filtered waste on its own; Andrews took no dialysis at all, and his appetite and strength returned. The kidney eventually failed because of clotting and was removed, and Andrews went back on dialysis — but three months later a human kidney came through. He has since resumed most of normal life, swimming and cycling included.

Why the "bridge" matters

The Lancet paper's significance is precisely that the pig kidney was not billed as permanent. Chinese readers following the story — Caixin ran it as a lead medical case feature — seized on the framing: a pig organ that reliably buys a patient months or years off dialysis could ease the desperate arithmetic of transplant waiting lists, where suitable human organs are scarce everywhere. Dialysis keeps people alive but steadily wears the body down; a functional interim organ changes what waiting for a transplant looks like.

China has its own stake in the field. In 2024, a surgical team at Xijing Hospital in Xi'an, led by the academician Dou Kefeng, performed Asia's first transplant of a multi-gene-edited pig kidney into a patient with end-stage renal disease — the fifth such procedure worldwide at the time. Chinese biotech is also under explicit policy instruction to close the gap with global first-in-class medicine: the health section of the current five-year plan targets a rising share of domestically originated new drugs.

The Weibo response to the Massachusetts case was notably free of the squeamishness the phrase "pig transplant" might once have drawn. Commenters debated clotting risk and asked when the procedure might reach Chinese hospitals — treating xenotransplantation less like science fiction than like a treatment whose turn is coming. The open question the case leaves is how long a bridge can be built: nine months is a landmark, but the destination is still a human organ.